This trial directly compared low-dose doxycycline against a standard dose of minocycline (a related tetracycline) in rosacea. Both reduced inflammatory bumps to a similar degree, so doxycycline was "not worse" than minocycline. Doxycycline was linked to fewer side effects, supporting low-dose doxycycline as a first-choice oral option for rosacea.